Cost-Effectiveness Analysis of 240 mg Sotorasib for KRAS-G12C Mutated Non-Small Cell Lung Cancer: A Payer Perspective in the US Market
Document Type
Presentation
Publication Date
11-13-2024
Abstract
Sotorasib is a recently approved targeted therapy for KRAS G12C-mutated non-small-cell lung cancer (NSCLC). Initially approved at a 960 mg dose, recent studies suggest a lower 240 mg dose may provide similar efficacy at reduced costs. This study evaluated the cost-effectiveness of 240 mg versus 960 mg of sotorasib from a U.S. payer perspective to inform potential dose optimization strategies. A partitioned survival model was constructed using data from Hochmair et al. and cost inputs from meta-analysis and systematic reviews and UptoDate. Key health states included progression-free survival, progressed disease, and death, with a 60-month time horizon and a 3% discount rate. Gompertz models were used to extrapolate survival beyond observed data. The base-case analysis yielded an incremental cost-effectiveness ratio (ICER) of $169,107 per quality-adjusted life year (QALY), slightly above the willingness-to-pay threshold of $150,000 per QALY. Sensitivity analyses with ±20% variations in cost and utilities produced ICERs ranging from $25,078 to $211,383. The AIC values suggested a better fit for the Gompertz model at the 240 mg dose, indicating consistent survival trends with lower dosing. Limitations included using different utility sources for progression-free and progressed states and reliance on digitized survival data. Overall, 240 mg sotorasib may offer a cost-effective alternative for managing KRAS G12C-mutated NSCLC, supporting the potential for dose optimization in line with FDA initiatives. Further studies are needed to validate these findings in real-world settings.
Recommended Citation
Bailey, PharmD, Drew, "Cost-Effectiveness Analysis of 240 mg Sotorasib for KRAS-G12C Mutated Non-Small Cell Lung Cancer: A Payer Perspective in the US Market" (2024). Master of Science in Applied Health Economics and Outcomes Research Capstone Presentations. Presentation 46.https://jdc.jefferson.edu/msaheor/46
Language
English
Comments
Presentation: 23:54